45 results about "Nerve Diseases" patented technology

The invention relates to a multistage self-anchoring flexible deep brain electrical stimulation electrode and a preparation method thereof, and relates to the technical field of medical instruments. A bionic root system-octopus whisker composite framework including a main electrode base, a second-stage fractal arm and a third-stage self-anchoring tail end is adopted, intelligent materials such as carbon nano tube / PDMS composite fibers, temperature-sensitive PNIPAAm hydrogel and a degradable PLGA-gelatin composite material are fused, and a mechanical lock catch and biological fusion dual-anchoring mechanism is constructed. The distributed electrode array comprises platinum-iridium alloy, graphene / PDMS and a titanium nitride nano electrode, and cross-scale stimulation from the nuclear group level to the single cell level is achieved. The intelligent regulation and control system solves the problems of brain tissue displacement and chronic inflammation through a pressure feedback degradation and flexible interconnection technology. Compared with a traditional product, the contact area of the electrode is increased by 5-8 times, the stimulation precision reaches the single cell level, and the electrode is suitable for long-term deep brain stimulation treatment of nerve diseases such as Parkinson's disease and epilepsy and has remarkable clinical application value.

A polypeptide linker (2 to 21 amino acids) is connected to a carrier peptide based on the Ioop2 domain of lynx1. The carrier or transporter peptide may be further coupled via the polypeptide linker to a molecule of interest (MOI) or effector agent, such as a protein or protein domain or any other biomolecule (e.g., biomolecules having a molecular weight of 10kDa to 230 kDa). In some embodiments, the complex may be used therapeutically in targeting various neurological disease-causing cellular components.

The present technology related to a genus of compounds which are prodrugs of arimoclomol. The present technology further relates to compositions comprising the same and methods of treating neurological diseases and disorders by administering said compounds.

The application discloses a cistema brain-computer interface-minimally invasive whole brain nerve signal acquisition and closed-loop control system based on a cerebrospinal fluid channel and a method thereof. The system comprises a flexible cistema interface array, an ultra-wideband wireless energy and data synchronous transmission module, a nerve signal analysis and decoding module, a self-adaptive closed-loop control module and a system integrated control platform. The flexible cistema interface array is implanted in a cerebrospinal fluid cavity in a minimally invasive manner to acquire multi-brain region nerve signals; and the ultra-wideband transmission module realizes energy supply and high-speed bidirectional communication between an implanted body and an extracorporeal device. The application solves the problems of a large trauma, limited coverage and poor signal quality of an existing invasive interface, has the advantages of minimally invasive, wide area coverage, high signal quality and good integration, and is suitable for diagnosis and treatment of neurological diseases such as epilepsy suppression and post-stroke motor function reconstruction.

Provided herein are antibodies and antigen-binding domains that specifically bind to human CD98 and their use in, for example, transport across the blood brain barrier (BBB). Among others, also provided herein are conjugates comprising these anti-CD98 antibodies and antigen-binding fragments, such as the conjugates with GLP-1R agonists, and their uses in, for example, treating or preventing neurological diseases or disorders and / or metabolic diseases or disorders.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Combination therapies comprising oxytocin and gonadotropin releasing hormone are provided. The combinations can be used to treat aging-related neurological diseases or disorders. In addition, downstream effectors of OXT-GnRH combination, including hypothalamic stem / progenitor cells-derived EVs and vesicles containing or loaded with PTMS, can be used to treat aging-related neurological diseases or disorders.

The present invention relates to the use of a culture medium-based method for inducing the specific differentiation of dental stem cells into dopaminergic neurons. The purpose of the present invention is to develop cell applications for treating degenerative neurological diseases and drugs related to the diseases.

The present invention addresses the problem of providing an agent for preventing or treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging, as well as a more stable antibody that exhibits an effect of preventing or treating these diseases, Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD). A human monoclonal antibody that specifically binds to human HMGB1, wherein the human monoclonal antibody (anti-human HMGB1 antibody) comprises a heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and a light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, is used as an agent for preventing or treating ALS, PD, HD, SCA, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen binding protein (e.g., scFv, Fab) conjugated to a molecular load (e.g., a polynucleotide, liposome, or lipid nanoparticle) for delivery of the molecular load to a target tissue (e.g., brain or muscle). Methods of treating various diseases or disorders, such as neurological or muscular diseases, with the conjugates are provided.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

A neural disease diagnosis system based on space-time attention and dynamic domain adaptation belongs to the technical field of cross-modal medical data adaptive analysis. It solves the technical problem that there is an urgent need for a new system that can simultaneously fuse multi-modal information, model multi-scale space-time features, and have dynamic domain adaptation capability to improve the accuracy and generalization ability of multi-site neural disease intelligent diagnosis. The system comprises: a data preprocessing module for extracting standardized time series of individual brain regions from fMRI time series data; a dual-channel feature encoding network module for obtaining global features through an attention mechanism; a feature fusion and classification module, wherein a main task classifier performs a main task to predict whether a testee has a neural disease, and a domain task classifier performs a domain task to predict the site to which the testee belongs; and a dynamic balance training module for adjusting the dynamic balance of the main task and the domain task through a dynamic balance control strategy.

The present invention addresses the problem of providing an agent for preventing or treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging, as well as a more stable antibody that exhibits an effect of preventing or treating these diseases, Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD). A human monoclonal antibody that specifically binds to human HMGB1, wherein the human monoclonal antibody (anti-human HMGB1 antibody) comprises a heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and a light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, is used as an agent for preventing or treating ALS, PD, HD, SCA, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

A method for identifying a cerebral edema or a cerebral microhemorrhage in a subject, the method including providing a sample obtained from the subject, comprising a level of one or more biomarkers, wherein the one or more biomarkers comprises one or more GLX-related GAGs, one or more GLX-related PGs, one or more GLX-related GPs, one or more GLX-related GLs, one or more GLX-related GCs, or one or more fragments thereof, or any combination of the aforementioned biomarkers; measuring or detecting the level of the one or more biomarkers in the sample; comparing the level of the one or more biomarkers measured or detected to a reference level for the one or more biomarkers; and identifying the subject as having a cerebral edema or a cerebral microhemorrhage if the level of the one or more of the biomarkers measured or detected from the sample are different than the reference level for the one or more biomarkers.

Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and / or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

The invention discloses a spinal degenerative nerve disease focus positioning method based on a multi-scale convolutional neural network, and belongs to the technical field of biomedical image processing. According to the method, through multi-scale image input, subdivision label construction and a multi-model training strategy, in combination with the target detection capability of YOLOv8, refined positioning and evaluation of the spinal degenerative nerve disease are realized, and a quantitative auxiliary tool is provided for clinical diagnosis. The core innovation of the method lies in a multi-dimensional label system and label shielding training, and the detection precision of serious lesions is improved.

Provided herein is a dendrimer complex comprising a 2-deoxyglucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.

The invention belongs to the field of chemical pharmacy. Relates to 4-methylquinazoline derivatives, and a preparation method, a pharmaceutical composition and application thereof. The 4-methylquinazoline derivative is a compound shown in a formula (I) or a pharmaceutically acceptable salt thereof, is a PI3K inhibitor, and can be used for preventing and / or treating diseases related to PI3K activity, such as tumors, autoimmune diseases, kidney diseases, cardiovascular diseases, inflammation, metabolism / endocrine dysfunction or nerve diseases.

This invention relates to compositions for the prevention or treatment of degenerative neurological diseases, comprising a compound that induces the expression of the anti-aging gene klotho as an active ingredient. The compound of this invention, expressed by chemical formula 1, exhibits excellent efficacy in increasing the expression level of the Klotho gene, a gene related to aging, and can be effectively used as a pharmaceutical composition or food composition for the prevention, improvement, or treatment of degenerative neurological diseases.

The present invention relates to a process for the industrial scale preparation of (3β,24S)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol, useful in counteracting the progression of highly disabling neurological diseases such as Alzheimer's, Parkinson's, and Huntington's disease, and having the structure shown below: The invention also relates to an improved method for the separation of two epimers that are obtained during the synthesis.

The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain or muscle). Methods for treating various diseases or disorders, such as neurological diseases or muscular diseases, with the conjugates are provided.

The invention discloses a multi-channel multi-mode active electrode integrated nerve probe chip for an implantable brain-computer interface, which comprises a non-implantable circuit part and an implantable electrode part, wherein the non-implanted circuit part integrates a multi-channel electroneurographic signal detection front end, a chemical signal detection front end, a multi-bit adjustable stimulation circuit, a reconfigurable switch array and digital control logic; the implantable electrode part is of a silicon needle structure, electrical electrodes and chemical electrodes are longitudinally distributed on the surface of the implantable electrode part, and dynamic gating and closed-loop regulation and control are supported. Through the electrode-circuit integrated design, the multi-mode function of synchronous high-precision detection and electrical stimulation output of the electroneurographic signals and the chemical signals is achieved, the problems that in the prior art, the mode is single, and the integration degree is low are solved, and the device has the advantages of being high in channel density and low in noise; 5 [mu] Vrms) and a fast closed-loop response (lt; the method is suitable for acute and long-term brain science research and nerve disease treatment.

This invention belongs to the field of pharmaceutical technology and relates to thienopyrimidine derivatives, their preparation methods, uses, and pharmaceutical compositions. The thienopyrimidine derivatives, as shown in formula (I), are phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors and can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, kidney diseases, cardiovascular diseases, inflammation, metabolic / endocrine dysfunction, or neurological diseases.

The invention discloses a nerve disease medicine composition and a preparation method and application thereof, the medicine composition contains active ingredients of edaravone, borneol and blumea balsamifera, and the weight ratio of the borneol and the blumea balsamifera in the three active ingredients is 10%-35%, preferably 15%-25%. According to the pharmaceutical composition disclosed by the invention, in free radical scavenging and ALS pharmacodynamic tests, when the weight ratio of the borneol to the blumea balsamifera in the three active ingredients is 10%-35% and the blumea balsamifera accounts for 0.05%-1.5% of the weight of the borneol, the pharmacodynamic effect is optimal; the anti-inflammatory effect is very good; the L-borneol has low dose dependence on the enhancement effect of the permeability of the blood brain barrier, and the transmembrane transport of the medicine can be obviously promoted within the concentration range of 0.05-1.5%.

This invention belongs to the field of microfluidic organ-on-a-chip technology, and relates to an assemblable multi-cell co-culture brain organ-on-a-chip and its applications. The multi-cell co-culture brain organ-on-a-chip consists of a lower substrate, a middle chip, and an upper chip. The upper chip has one cell culture chamber and eight inlet / outlet ports, while the middle chip has seven cell culture chambers. The six cell culture chambers are arranged in a hexagonal pattern around the central chamber, and adjacent chambers are interconnected through a micro-forestation structure. The lower substrate serves as a supporting base. Compared with existing brain organ-on-a-chips, this chip device can effectively induce and stably generate Lewy bodies, and can reproduce typical pathological features of Parkinson's disease that are difficult to achieve with traditional chips. It is particularly suitable for simulating the blood-brain barrier and co-culture systems of brain parenchymal cells, providing novel device support for the study of Parkinson's disease mechanisms and in vitro drug screening, and has significant application value in the fields of neurological disease model construction and drug development.

The invention relates to the technical field of natural product extraction, in particular to a torreya grandis crude polysaccharide extraction method and application of the torreya grandis crude polysaccharide in neuronal differentiation.The torreya grandis crude polysaccharide is extracted through an ultrasonic wave-microwave-enzyme method combined auxiliary extraction technology, the polysaccharide content is detected to be 67.92% through a phenol-sulfuric acid method, the relative molecular mass is 3000 kDa, and the content of the polysaccharide in the torreya grandis crude polysaccharide is 87.92%. A novel method is provided for a torreya grandis polysaccharide extraction process; besides, activity research is carried out on the extracted torreya grandis crude polysaccharide, the torreya grandis crude polysaccharide can promote bone marrow-derived mesenchymal stem cells (BMSCs) to differentiate into neuronal cells, mRNA expression of neuron specific markers Netin, MAP2 and VEGF-A in the BMSCs is increased, the protein level of neuronal differentiation related genes beta-tubin III, Thy-1 and Enolase is up-regulated, and the effect of promoting the differentiation of the neuronal cells is achieved. A good nerve repairing effect is embodied, and the material is expected to be applied to clinical treatment of nerve diseases.

The present invention relates to a composition comprising a mixture of molecules, said mixture comprising at least chrysin, pinocembrin and CAPE, for its use in the prevention or treatment of neuroinflammation and / or diseases or disorders associated with neuroinflammation.

The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of neurological diseases / disorders involving Na+—K+-2Cl−—cotransporters (NKCCs), such as stroke, traumatic brain injury (TBI), spinal cord injury (SCI), peripheral nerve injury (PNI), brain edema, or glioma, and particularly for use in the treatment or prevention of stroke. The invention likewise relates to a method of treating or preventing a neurological disease or disorder involving an NKCC, such as stroke, TBI, SCI, PNI, brain edema, or glioma, the method comprising administering a compound of formula (I) to a subject in need thereof.

Provided herein is a dendrimer complex comprising a 2-deoxy glucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.